person · Reporting owner

LOVE TED W

Disclosed activity across 10 companies

Tapewire entity: 893
SEC CIK: 0001188919

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMICUS THERAPEUTICS, INC.FOLD · Entity 51196	Director	June 04, 2020	June 08, 2020
GILEAD SCIENCES, INC.GILD · Entity 405	Director	April 30, 2026	May 04, 2026
Jazz Pharmaceuticals plcJAZZ · Entity 818	Director	August 31, 2026	September 02, 2026
LISATA THERAPEUTICS, INC.LSTA · Entity 7814	Director	September 17, 2026	September 29, 2026
Royalty Pharma plcRPRX · Entity 3100	Director	June 05, 2026	June 08, 2026
Structure Therapeutics Inc.GPCR · Entity 1222	Director	June 17, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMICUS THERAPEUTICS, INC.

Report date June 04, 2020 · Filed June 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	131,000	Reported balance After 2020-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-06-04 · Grant · Acquired 5,855 · Balance 131,000 F1: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04	Direct	18,574	Reported balance After 2020-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-06-04 · Grant · Acquired 18,574 · Balance 18,574 F2: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.

F2: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant.

GILEAD SCIENCES, INC.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,484	Reported balance After 2026-04-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-04-30 · Grant · Acquired 1,146 · Balance 5,484 F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $130.84 · Expires 2036-04-30	Direct	4,884	Reported balance After 2026-04-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-30 · Grant · Acquired 4,884 · Balance 4,884 F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Jazz Pharmaceuticals plc

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	2,389	Ending reported balance After 2026-08-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-31 · Tax withholding · Disposed 6 · Balance 3,126 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 737 · Balance 2,389 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

LISATA THERAPEUTICS, INC.

Report date September 17, 2026 · Filed September 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,260	Reported balance Holding disclosure · report date 2026-09-17 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 19,260 F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 2,354,899 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's F2: (continued from Footnote 1) common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.
Series C Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F3: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 2,354,899 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's F2: (continued from Footnote 1) common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 2,354,899 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's

F2: (continued from Footnote 1) common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.

F3: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date.

Royalty Pharma plc

Report date June 05, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	58,393	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 58,393 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Structure Therapeutics Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16	Direct	39,453	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,

F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cascadian Therapeutics, Inc.

Report date March 09, 2018 · Filed March 13, 2018

Section 16 reporting ended · disclosed 2018-03-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-03-09 transaction · row 1 1 source row Row 1 · 2018-03-09 · Other · Disposed 37,394 · Balance 0 F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-09 · Disposition to issuer · Disposed 13,927 · Balance 0 F2: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F3: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date. F4: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.

F2: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.

F3: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date.

F4: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 576,318 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Trust 1	Reported balance After 2022-10-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 119,650 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Trust 2	Reported balance After 2022-10-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 119,650 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Trust 3	Reported balance After 2022-10-05 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 102,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Daughter	Reported balance After 2022-10-05 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 2,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Daughter	Reported balance After 2022-10-05 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 2,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-05 · Disposition to issuer · Disposed 11,250 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-05 · Disposition to issuer · Disposed 26,865 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-05 · Disposition to issuer · Disposed 47,223 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-10-05 · Disposition to issuer · Disposed 63,768 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-10-05 · Disposition to issuer · Disposed 109,116 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-10-05 · Disposition to issuer · Disposed 141,400 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40	Direct	Reported balance After 2022-10-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-10-05 · Disposition to issuer · Disposed 114,515 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.60	Direct	Reported balance After 2022-10-05 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2022-10-05 · Disposition to issuer · Disposed 122,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.44	Direct	Reported balance After 2022-10-05 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2022-10-05 · Disposition to issuer · Disposed 145,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.82	Direct	Reported balance After 2022-10-05 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2022-10-05 · Disposition to issuer · Disposed 114,190 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.48	Direct	Reported balance After 2022-10-05 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2022-10-05 · Disposition to issuer · Disposed 132,433 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.87	Direct	Reported balance After 2022-10-05 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2022-10-05 · Disposition to issuer · Disposed 118,090 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 1 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 15,575 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11	Direct	Reported balance After 2020-07-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F2: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 14,812 · Balance 0 F3: In connection with the Merger, these options were accelerated and canceled without payment.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.

F2: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F3: In connection with the Merger, these options were accelerated and canceled without payment.

Seagen Inc.

Report date December 14, 2023 · Filed December 15, 2023

Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-12-14 transaction · row 1 1 source row Row 1 · 2023-12-14 · Disposition to issuer · Disposed 4,255 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.82 · Expires 2030-08-17	Direct	Reported balance After 2023-12-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-12-14 · Disposition to issuer · Disposed 4,460 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $147.50 · Expires 2031-05-14	Direct	Reported balance After 2023-12-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-12-14 · Disposition to issuer · Disposed 3,462 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.63 · Expires 2032-05-13	Direct	Reported balance After 2023-12-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-12-14 · Disposition to issuer · Disposed 3,676 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-12-14 · Disposition to issuer · Disposed 449 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").

F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.

F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 18, 2019 Filed Oct 2, 2019 16:20 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	8,294	$0.00	$0.00	Disclosure SEC source: 0001209191-19-051672 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,294 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs will vest, subject to Reporting Person's continuous service, annually over a three year period. F1 · balance_after: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs will vest, subject to Reporting Person's continuous service, annually over a three year period. Read SEC document
August 01, 2019 Filed Aug 5, 2019 21:17 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	11,250	$0.00	$0.00	Disclosure SEC source: 0000899243-19-021021 · doc4.xml · derivative · entry 7 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
August 01, 2019 Filed Aug 5, 2019 21:17 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	9,750	$0.00	$0.00	Disclosure SEC source: 0000899243-19-021021 · doc4.xml · derivative · entry 6 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 9,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
August 01, 2019 Filed Aug 5, 2019 21:17 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	12,062	$0.00	$0.00	Disclosure SEC source: 0000899243-19-021021 · doc4.xml · derivative · entry 5 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,188 Underlying: Common Stock · 12,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
August 01, 2019 Filed Aug 5, 2019 21:17 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	16,394	$54.25	$889,374.50	Disclosure SEC source: 0000899243-19-021021 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,177,867 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 33,062 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
August 01, 2019 Filed Aug 5, 2019 21:17 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	33,062	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-021021 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,194,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 27, 2019 Filed Jul 1, 2019 20:59 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	19,473	$0.00 Strike: $12.00	$0.00	Disclosure SEC source: 0001209191-19-039764 · doc4.xml · derivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 Underlying: Common Stock · 19,473 shares Expires 2029-06-27 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2020. Read SEC document
June 27, 2019 Filed Jul 1, 2019 20:59 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	6,250	$0.00	$0.00	Disclosure SEC source: 0001209191-19-039764 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,145 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock. Read SEC document
April 08, 2019 Filed Apr 10, 2019 20:16 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	35,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-010474 · doc4.xml · derivative · entry 6 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On April 8, 2019, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On April 8, 2019, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
April 08, 2019 Filed Apr 10, 2019 20:16 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	17,354	$58.51	$1,015,382.54	Disclosure SEC source: 0000899243-19-010474 · doc4.xml · nonDerivative · entry 3 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161,199 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 35,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
April 08, 2019 Filed Apr 10, 2019 20:16 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	35,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-010474 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,178,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 01, 2019 Filed Feb 5, 2019 22:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	9,750	$0.00	$0.00	Disclosure SEC source: 0000899243-19-002666 · doc4.xml · derivative · entry 8 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,500 Underlying: Common Stock · 9,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F6 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2019 Filed Feb 5, 2019 22:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	12,063	$0.00	$0.00	Disclosure SEC source: 0000899243-19-002666 · doc4.xml · derivative · entry 7 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,250 Underlying: Common Stock · 12,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2019 Filed Feb 5, 2019 22:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	90,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-002666 · doc4.xml · derivative · entry 6 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2019 Filed Feb 5, 2019 22:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	145,000	$0.00 Strike: $48.44	$0.00	Disclosure SEC source: 0000899243-19-002666 · doc4.xml · derivative · entry 5 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2029-01-31 F3 · derivative.exercise_date: The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2019 Filed Feb 5, 2019 22:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	7,814	$48.44	$378,510.16	Disclosure SEC source: 0000899243-19-002666 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,142,974 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 21,813 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
February 01, 2019 Filed Feb 5, 2019 22:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	21,813	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-002666 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
January 31, 2019 Filed Apr 10, 2019 20:16 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantCommon Stock	579	$36.68	$21,237.72	Disclosure SEC source: 0000899243-19-010474 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,553 F1 · shares: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
August 01, 2018 Filed Aug 3, 2018 21:50 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	9,750	$0.00	$0.00	Disclosure SEC source: 0000899243-18-021420 · doc4.xml · derivative · entry 6 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,250 Underlying: Common Stock · 9,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in eight equal semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. F4 · derivative.expiration_date: The RSUs vest in eight equal semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. Read SEC document
August 01, 2018 Filed Aug 3, 2018 21:50 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	12,062	$0.00	$0.00	Disclosure SEC source: 0000899243-18-021420 · doc4.xml · derivative · entry 5 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,313 Underlying: Common Stock · 12,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in eight equal semi-annual installments after February 1, 2017 until fully vested on February 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in eight equal semi-annual installments after February 1, 2017 until fully vested on February 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. Read SEC document
August 01, 2018 Filed Aug 3, 2018 21:50 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	10,816	$43.15	$466,710.40	Disclosure SEC source: 0000899243-18-021420 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,128,975 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,250 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
August 01, 2018 Filed Aug 3, 2018 21:50 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	21,812	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-021420 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,139,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
July 16, 2018 Filed Jul 18, 2018 01:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	12,194	$0.00 Strike: $16.40	$0.00	Disclosure SEC source: 0000899243-18-019983 · doc4.xml · derivative · entry 4 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,806 Underlying: Common Stock · 12,194 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying the option vest in equal quarterly installments over 16 quarters from January 17, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F1 · derivative.expiration_date: The shares underlying the option vest in equal quarterly installments over 16 quarters from January 17, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
July 16, 2018 Filed Jul 18, 2018 01:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	12,194	$16.40	$199,981.60	Disclosure SEC source: 0000899243-18-019983 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,117,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 07, 2018 Filed Jun 11, 2018 20:42 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	8,912	$0.00 Strike: $16.23	$0.00	Disclosure SEC source: 0001209191-18-036995 · doc4.xml · derivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,912 Underlying: Common Stock · 8,912 shares Expires 2028-06-07 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019. Read SEC document
June 07, 2018 Filed Jun 11, 2018 20:42 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	3,081	$0.00	$0.00	Disclosure SEC source: 0001209191-18-036995 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:11 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerRestricted Stock Units · Derivative	13,927	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-007307 · doc4.xml · derivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,927 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F2 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F3 · derivative.exercise_date: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date. F4 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:11 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	OtherCommon Stock	37,394	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-007307 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. Read SEC document
February 14, 2018 Filed Feb 17, 2018 00:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	35,000	$0.00	$0.00	Disclosure SEC source: 0000899243-18-004446 · doc4.xml · derivative · entry 5 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,500 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F4 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 14, 2018 Filed Feb 17, 2018 00:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	17,353	$62.30	$1,081,091.90	Disclosure SEC source: 0000899243-18-004446 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105,785 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 35,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
February 14, 2018 Filed Feb 17, 2018 00:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	35,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-004446 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F2 · balance_after: Includes 996 shares acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") on January 31, 2018, in a transaction exempt under Rule 16b-3. Read SEC document
February 01, 2018 Filed Feb 3, 2018 00:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	78,000	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002738 · doc4.xml · derivative · entry 10 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F7 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2018 Filed Feb 3, 2018 00:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	122,000	$0.00 Strike: $59.60	$0.00	Disclosure SEC source: 0000899243-18-002738 · doc4.xml · derivative · entry 9 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,000 Underlying: Common Stock · 122,000 shares Expires 2028-01-31 F6 · derivative.exercise_date: The shares underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2018 Filed Feb 3, 2018 00:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	12,063	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002738 · doc4.xml · derivative · entry 8 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,375 Underlying: Common Stock · 12,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On January 17, 2017, the Reporting Person was granted 96,500 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: On January 17, 2017, the Reporting Person was granted 96,500 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2018 Filed Feb 3, 2018 00:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	5,981	$59.60	$356,467.60	Disclosure SEC source: 0000899243-18-002738 · doc4.xml · nonDerivative · entry 4 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,087,142 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 12,063 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
February 01, 2018 Filed Feb 3, 2018 00:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	12,063	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-002738 · doc4.xml · nonDerivative · entry 3 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,093,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
January 31, 2018 Filed Feb 3, 2018 00:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	35,000	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002738 · doc4.xml · derivative · entry 7 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
January 31, 2018 Filed Feb 3, 2018 00:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	17,353	$57.90	$1,004,738.70	Disclosure SEC source: 0000899243-18-002738 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,081,060 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 35,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
January 31, 2018 Filed Feb 3, 2018 00:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	35,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-002738 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
January 24, 2018 Filed Jan 26, 2018 22:26 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	35,000	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002118 · doc4.xml · derivative · entry 5 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 24, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 24, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
January 24, 2018 Filed Jan 26, 2018 22:26 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	17,354	$58.15	$1,009,135.10	Disclosure SEC source: 0000899243-18-002118 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,413 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 35,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
January 24, 2018 Filed Jan 26, 2018 22:26 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	35,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-002118 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document
January 16, 2018 Filed Jan 19, 2018 00:38 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	35,000	$0.00	$0.00	Disclosure SEC source: 0000899243-18-001364 · doc4.xml · derivative · entry 5 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,500 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 16, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 16, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
January 16, 2018 Filed Jan 19, 2018 00:38 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	17,083	$52.10	$890,024.30	Disclosure SEC source: 0000899243-18-001364 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,045,767 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 35,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
January 16, 2018 Filed Jan 19, 2018 00:38 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	35,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-001364 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document
September 24, 2017 Filed Sep 26, 2017 17:21 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionRestricted Share Unit (RSU) · Derivative	2,375	$0.00	$0.00	Disclosure SEC source: 0001209191-17-054018 · doc4.xml · derivative · entry 3 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: The RSU was 100% vested on September 24, 2017. F3 · derivative.expiration_date: The RSU was 100% vested on September 24, 2017. Read SEC document
September 24, 2017 Filed Sep 26, 2017 17:21 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Tax withholdingCommon Stock	594	$3.94	$2,340.36	Disclosure SEC source: 0001209191-17-054018 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,394 F1 · shares: 594 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on September 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on September 22, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 594 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on September 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on September 22, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document
September 24, 2017 Filed Sep 26, 2017 17:21 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionCommon Stock	2,375	$0.00	$0.00	Disclosure SEC source: 0001209191-17-054018 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2017 Filed Aug 15, 2017 01:45 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	262,500	$0.00	$0.00	Disclosure SEC source: 0000899243-17-020279 · doc4.xml · derivative · entry 4 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
August 11, 2017 Filed Aug 15, 2017 01:45 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	124,106	$3.40	$421,339.87	Disclosure SEC source: 0000899243-17-020279 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,850 F1 · kind: Represents unvested shares of Common Stock repurchased by the Issuer at the original purchase price paid by the Reporting Person because the conditions for the vesting of such shares were not achieved within the timeframes specified for such vesting. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.